Literature DB >> 20885804

Prevention of respiratory syncytial virus infection.

L Samson.   

Abstract

Respiratory syncytial virus (RSV) infection is the leading cause of lower respiratory tract infection in young children, with significant numbers of premature infants and those with other risk factors requiring hospitalization in Canada each year. Palivizumab, an RSV-specific monoclonal antibody, can reduce the hospitalization rate and severity of illness for a small group of high-risk or premature infants during their first RSV season. The present statement reviews the published literature and provides recommendations regarding its use in premature and other at-risk infants, for Canadian physicians.

Entities:  

Keywords:  At-risk infants; Palivizumab; Prematurity; Prophylaxis; RSV

Year:  2009        PMID： 20885804      PMCID： PMC2780968          DOI： 10.1093/pch/14.8.521

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


  40 in total

1.  Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

Authors:  B Law; N Macdonald; J Langley; I Mitchell; D Stephens; E Wang; J Robinson; F Boucher; J McDonald; S Dobson
Journal:  Paediatr Child Health       Date:  1998-11       Impact factor: 2.253

2.  Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children : a case-control study.

Authors:  Anna Banerji; David Greenberg; Laura Forsberg White; W Alexander Macdonald; Audrey Saxton; Eva Thomas; Douglas Sage; Muhammad Mamdani; Krista L Lanctôt; James B Mahony; Mia Dingle; Ann Roberts
Journal:  Pediatr Infect Dis J       Date:  2009-08       Impact factor: 2.129

3.  Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-10       Impact factor: 2.253

4.  Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Authors:  Mark J C Nuijten; Wolfgang Wittenberg; Maximilian Lebmeier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada.

Authors:  S R Arnold; E E Wang; B J Law; F D Boucher; D Stephens; J L Robinson; S Dobson; J M Langley; J McDonald; N E MacDonald; I Mitchell
Journal:  Pediatr Infect Dis J       Date:  1999-10       Impact factor: 2.129

6.  Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

Authors:  Carole A Reeve; John S Whitehall; Petra G Buettner; Robert Norton; David M Reeve; Fleur Francis
Journal:  J Paediatr Child Health       Date:  2006-05       Impact factor: 1.954

7.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.

Authors:  E E Wang; B J Law; F D Boucher; D Stephens; J L Robinson; S Dobson; J M Langley; J McDonald; N E MacDonald; I Mitchell
Journal:  J Pediatr       Date:  1996-09       Impact factor: 4.406

8.  The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .

Authors:  Krista L Lanctôt; Shababa T Masoud; Bosco A Paes; Jean-Eric Tarride; Aaron Chiu; Charles Hui; Philip L Francis; Paul I Oh
Journal:  Curr Med Res Opin       Date:  2008-10-16       Impact factor: 2.580

9.  The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.

Authors:  Barbara J Law; Joanne M Langley; Upton Allen; Bosco Paes; David S C Lee; Ian Mitchell; John Sampalis; Hervé Walti; Joan Robinson; Karel O'Brien; Carina Majaesic; Georges Caouette; Lyne Frenette; Nicole Le Saux; Brian Simmons; Sharon Moisiuk; Koravanagattu Sankaran; Cecil Ojah; Avash J Singh; Marc H Lebel; Godfrey S Bacheyie; Heather Onyett; Andrea Michaliszyn; Patricia Manzi; Diana Parison
Journal:  Pediatr Infect Dis J       Date:  2004-09       Impact factor: 2.129

10.  Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study.

Authors:  Beatrijs L P Bloemers; A Marceline van Furth; Michel E Weijerman; Reinoud J B J Gemke; Chantal J M Broers; Kimberly van den Ende; Jan L L Kimpen; Jan L M Strengers; Louis J Bont
Journal:  Pediatrics       Date:  2007-10       Impact factor: 7.124
View more
  13 in total

1.  Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  Can Fam Physician       Date:  2010-10       Impact factor: 3.275

2.  Cost-effectiveness of palivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic.

Authors:  Anna Banerji; Kaspar Ng; Theo J Moraes; Vladimir Panzov; Joan Robinson; Bonita E Lee
Journal:  CMAJ Open       Date:  2016-10-18

3.  Are we too passive in our attempts to prevent respiratory syncytial virus infection in Northern Canada?

Authors:  Theo Moraes
Journal:  Can Respir J       Date:  2014 May-Jun       Impact factor: 2.409

4.  Respiratory syncytial virus prevention in children with congenital heart disease: who and how?

Authors:  Nam Kyun Kim; Jae Young Choi
Journal:  Korean J Pediatr       Date:  2011-05-31

5.  Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.

Authors:  Junyan Han; Katsuyuki Takeda; Meiqin Wang; Wanjiang Zeng; Yi Jia; Yoshiki Shiraishi; Masakazu Okamoto; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2014-07       Impact factor: 6.914

Review 6.  Impact of respiratory syncytial virus: the nurse's perspective.

Authors:  Marianne Bracht; Debbie Basevitz; Marilyn Cranis; Rose Paulley
Journal:  Drugs R D       Date:  2011-09-01

7.  Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.

Authors:  B Paes; I Mitchell; A Li; K L Lanctôt
Journal:  Eur J Pediatr       Date:  2011-12-28       Impact factor: 3.183

Review 8.  Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.

Authors:  Colleen Wegzyn; Lim Kai Toh; Gerard Notario; Sophie Biguenet; Kristina Unnebrink; Caroline Park; Doris Makari; Michael Norton
Journal:  Infect Dis Ther       Date:  2014-10-09

9.  Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).

Authors:  Zbyněk Straňák; Elie Saliba; Paraskevi Kosma; Klara Posfay-Barbe; Khalid Yunis; Teresa Farstad; Kristina Unnebrink; Jean van Wyk; Colleen Wegzyn; Gerard Notario; Stefanie Kalus; Fiona J Campbell
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

Review 10.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease.

Authors:  Josep Figueras-Aloy; Paolo Manzoni; Bosco Paes; Eric A F Simões; Louis Bont; Paul A Checchia; Brigitte Fauroux; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2016-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.